25 September, 2020

The regulatory approval and commercialisation of Luxturna in 2017 has opened the floodgates for gene therapy, with numerous clinical trials underway or rapidly approaching. Dr Tom Edwards and Dr Lauren Ayton will update Retina Australia members on the national approach to identifying and characterising people who might be eligible for these trials (through the Inherited Retinal Disease Natural History Study), as well as describing the most promising developments in the field.

This webinar will take place on Saturday 17th October at 2:00pm EST. You can find a copy of the flyer in Word version here or in PDF version here

Back to News

We can’t do what we do without you!

Other News

Top 10 Research Priorities for Inherited Retinal Disease

We are thrilled to share the Top 10 Research Priorities for Inherited Retinal Disease,...

Launch of the Geographic Atrophy Case for Action Report

The Parliamentary Friends for Eye Health and Vision Care The Geographic Atrophy Case for Action...

$4M MRFF Grant awarded for National Platform for Therapeutic mRNA Development

The Australian Government's Medical Research Future Fund (MRFF) has...